Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations

Abstract excerpt

Significance A variety of rare mutations account for 10–20% of EGFR mutations in nonsmall cell lung cancer. However, due to high diversity, proper medication for patients with such mutations is impossible in daily clinic. To appropriately treat lung cancer patients harboring such rare EGFR mutations, a robust prediction model to predict sensitivities of rare EGFR mutants to existing drugs is strongly needed....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to Cancer therapeutics and mechanisms
• Share to Lung Cancer Treatments and Mutations